Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

New era of early cancer detection blood tests on the horizon

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19

New data presented at ESMO for multi-cancer early detection

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence

Working to improve global cancer care access in low middle-income countries

Physical activity improves quality of life for patients with pancreatic cancer

Cancer patient symptom and physical function reporting by caregivers used as predictors of adverse clinical outcomes

War in Ukraine: Global cancer aid to support refugees

ASCO and WHO to collaborate on quality indicators for cancer facilities

Spotlight on global cancer control at ASCO 2022